News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Genmab A/S (DK:GEN) And ACE BioSciences To Develop Product To Treat Fungal Infections

10/19/2005 5:10:47 PM

COPENHAGEN, Denmark, Nov. 17 /PRNewswire-FirstCall/ -- Genmab A/S and privately held ACE BioSciences A/S announced today that they will develop an antibody therapeutic product with the potential to treat fungal infections. The antibody will be directed against a novel target on Aspergillus fumigatus. This fungus can cause life threatening infections in patients whose immune systems are compromised, for example cancer patients receiving chemotherapy.

The target discovered by ACE BioSciences is the first in the collaboration between Genmab and ACE BioSciences that covers four commercially promising disease targets in the area of infectious diseases. Under the agreement, ACE BioSciences provides novel commercially promising disease targets and Genmab provides human antibody technology to create and develop new antibody products. The two companies share development costs and commercial rights equally.

"After only two years of operation ACE BioSciences has found and validated a significant number of novel protein targets for new treatments of Aspergillus fumigatus," said Ejvind Mortz, Ph.D., Chief Executive Officer of ACE BioSciences'. "With Genmab we have chosen a promising novel protein target for which Genmab will use their expertise in developing human antibodies for treatment of aspergillosis."

"ACE BioSciences's target discovery skills and Genmab's antibody development capabilities are an ideal combination for discovery and development of antibody based treatments for infectious diseases," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "Fungal infections are becoming an increasingly urgent health threat and, despite not being adequately treated, currently represent a multi-billion dollar market."

About Aspergillus fumigatus

Aspergillus fumigatus is an opportunistic pathogen that causes fungal infections in immunocompromised patients but not generally in healthy individuals who are not susceptible to the disease. In recent years the number of patients with invasive aspergillosis has increased significantly, due to three main reasons: first, the increasing use of chemotherapy for treatment of cancer; second, the increase of transplantation patients treated with immunosuppressive drugs; and third, the increased number of patients with suppressed immune systems, such as AIDS patients. Infection can occur in the lungs and in many organs and tissues, such as heart, liver, eye, nose, ear and skeletal muscle, resulting in conditions such as allergic aspergillosis, aspergilloma and invasive aspergillosis. Early diagnosis, treatment and prevention are very difficult. Drugs such as itraconazole have been used for many years as a treatment, but even so, mortality is still as high as 60-90%.

The US antifungal market was approximately $2.9 billion in 2002. The average annual growth rate in this market is 11%, primarily driven by the growing at-risk population.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit

About ACE BioSciences A/S

ACE BioSciences is a biotechnology company focused on the development of novel targets and drug leads for infectious diseases caused by bacteria and fungi. The company is situated in Odense, Denmark, in the heart of the strongest proteomics cluster in Europe. ACE BioSciences was founded in 2001 and has in less than two years established a unique technology platform (INPRINT(TM)) integrating infectious disease biology with proteomics and bioinformatics. The technology enables ACE BioSciences to discover and validate novel protein targets in a wide range of infectious bacteria and fungi. ACE BioSciences collaborates with the biotechnology industry, the pharmaceutical industry and academia to use novel targets discovered by ACE BioSciences for development of antimicrobial therapies based on antibodies, vaccines and small molecule drugs. For more information about ACE BioSciences, visit

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects.

Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab A/S

CONTACT: Sisse P. Hansen Investor & Public Relations of Genmab A/S,+45-33-44-77-76, or mobile, +45-25-27-47-27,; Ejvind Mortz, CEOof ACE BioSciences A/S, +45-65-65-20-30, or mobile, +45-40-28-50-10,

Read at

comments powered by Disqus